4586 Medrx Co.,Ltd.メドレックスTSE Growth / Pharmaceuticals
1 post
Medrx Co.,Ltd. stock hit limit-up on Nov 20: what happened
It closed at ¥107 on Nov 20 (+¥60.0, +127.66%), limit-up, ranking #1 among the top gainers of all stocks on the Tokyo Stock Exchange.
No disclosures were found for this stock around that day. Share what you know in the posts below.
Changes are calculated from the closing prices this site collects daily; limit-up/down is an estimate based on the daily price limit. Please make your own investment decisions.
Medrx Co.,Ltd. (4586) at a glance
Prices are from Yahoo! Finance and may be delayed. Always check the latest price before trading.
Medrx Co.,Ltd. (4586) Stock Price History
Medrx Co.,Ltd. closed at ¥107 on Nov 20, 2026, +109.8% over 1 month, −12.3% over 1 year.
If you had invested ¥100,000 1 month ago, it would be worth ¥209,804 today (+109.8%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved −11.9%, while this stock moved +109.8%.
Board sentiment (last 30 days): 100% bullish / 0% bearish (1 votes)
Last 10 Trading Days
| Date | Close | Change | % Change |
|---|---|---|---|
| Nov 20 (Fri) | ¥107 | +60 | +127.66% |
| Nov 18 (Wed) | ¥47.0 | −3 | −6.00% |
| Nov 17 (Tue) | ¥50.0 | +11 | +28.21% |
| Nov 16 (Mon) | ¥39.0 | +1 | +2.63% |
| Nov 13 (Fri) | ¥38.0 | +0 | +0.00% |
| Nov 12 (Thu) | ¥38.0 | −2 | −5.00% |
| Nov 11 (Wed) | ¥40.0 | +0 | +0.00% |
| Nov 10 (Tue) | ¥40.0 | +2 | +5.26% |
| Nov 9 (Mon) | ¥38.0 | +0 | +0.00% |
| Nov 6 (Fri) | ¥38.0 | −4 | −9.52% |
If you had invested ¥100,000 3 months ago, it would be worth ¥162,121 today (+62.1%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved −14.8%, while this stock moved +62.1%.
Board sentiment (last 30 days): 100% bullish / 0% bearish (1 votes)
Last 10 Trading Days
| Date | Close | Change | % Change |
|---|---|---|---|
| Nov 20 (Fri) | ¥107 | +60 | +127.66% |
| Nov 18 (Wed) | ¥47.0 | −3 | −6.00% |
| Nov 17 (Tue) | ¥50.0 | +11 | +28.21% |
| Nov 16 (Mon) | ¥39.0 | +1 | +2.63% |
| Nov 13 (Fri) | ¥38.0 | +0 | +0.00% |
| Nov 12 (Thu) | ¥38.0 | −2 | −5.00% |
| Nov 11 (Wed) | ¥40.0 | +0 | +0.00% |
| Nov 10 (Tue) | ¥40.0 | +2 | +5.26% |
| Nov 9 (Mon) | ¥38.0 | +0 | +0.00% |
| Nov 6 (Fri) | ¥38.0 | −4 | −9.52% |
If you had invested ¥100,000 6 months ago, it would be worth ¥152,857 today (+52.9%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved −8.5%, while this stock moved +52.9%.
Monthly Closes
| Month | Month-End Close | Monthly % |
|---|---|---|
| Nov 2026 | ¥107 | +127.7% |
| Oct 2026 | ¥47.0 | −19.0% |
| Sep 2026 | ¥58.0 | −10.8% |
| Aug 2026 | ¥65.0 | −1.5% |
| Jul 2026 | ¥66.0 | +20.0% |
| Jun 2026 | ¥55.0 | −15.4% |
| May 2026 | ¥65.0 | −16.7% |
If you had invested ¥100,000 1 year ago, it would be worth ¥87,705 today (−12.3%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved +13.3%, while this stock moved −12.3%.
Monthly Closes
| Month | Month-End Close | Monthly % |
|---|---|---|
| Nov 2026 | ¥107 | +127.7% |
| Oct 2026 | ¥47.0 | −19.0% |
| Sep 2026 | ¥58.0 | −10.8% |
| Aug 2026 | ¥65.0 | −1.5% |
| Jul 2026 | ¥66.0 | +20.0% |
| Jun 2026 | ¥55.0 | −15.4% |
| May 2026 | ¥65.0 | −16.7% |
| Apr 2026 | ¥78.0 | −27.1% |
| Mar 2026 | ¥107 | +0.9% |
| Feb 2026 | ¥106 | −8.6% |
| Jan 2026 | ¥116 | +7.4% |
| Dec 2025 | ¥108 | −12.2% |
| Nov 2025 | ¥123 | ― |
If you had invested ¥100,000 3 years ago, it would be worth ¥66,460 today (−33.5%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved +67.8%, while this stock moved −33.5%.
Yearly Closes
| Year | Year-End Close | Yearly % |
|---|---|---|
| 2026 (YTD) | ¥107 | −0.9% |
| 2025 | ¥108 | ― |
If you had invested ¥100,000 5 years ago, it would be worth ¥76,978 today (−23.0%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved +96.3%, while this stock moved −23.0%.
Yearly Closes
| Year | Year-End Close | Yearly % |
|---|---|---|
| 2026 (YTD) | ¥107 | −0.9% |
| 2025 | ¥108 | ― |
If you had invested ¥100,000 in Mar 2013, it would be worth ¥2,997 today (−97.0%).Price change only; dividends and fees are not included.
Over the same period the Nikkei 225 moved +355.2%, while this stock moved −97.0%.
Yearly Closes
| Year | Year-End Close | Yearly % |
|---|---|---|
| 2026 (YTD) | ¥107 | −0.9% |
| 2025 | ¥108 | +31.7% |
| 2024 | ¥82.0 | −45.7% |
| 2023 | ¥151 | +58.9% |
| 2022 | ¥95.0 | −25.8% |
| 2021 | ¥128 | −39.3% |
| 2020 | ¥211 | −30.6% |
| 2019 | ¥304 | −45.5% |
| 2018 | ¥558 | −53.1% |
| 2017 | ¥1,190 | +149.5% |
| 2016 | ¥477 | −14.8% |
| 2015 | ¥560 | −35.8% |
| 2014 | ¥872 | −51.8% |
| 2013 | ¥1,811 | ― |
Daily, weekly and monthly closes (Yahoo! Finance, split-adjusted, dividends excluded). "All" covers the range Yahoo provides (from Mar 2013). Please check the latest prices before trading.
Medrx Co.,Ltd. (4586) financial indicators
PER, ROE and dividend yield are based on company forecasts, calculated from earnings reports and the closing price after each trading day.
Key features of Medrx Co.,Ltd. (4586)
Business overview
Together with two consolidated subsidiaries, the company is a drug discovery group creating new pharmaceuticals based on its own transdermal formulation technology. Centered on ILTS, its own transdermal formulation technology using the properties of ionic liquids, and NCTS, which uses nano-colloid drug technology, it aims to develop drugs with new added value by maximizing efficacy, reducing side effects, preventing missed doses and enabling administration to patients who have difficulty taking drugs orally. While developing candidate formulations created with its technology toward approval, it advances its business by forming development, sales and manufacturing partnerships with pharmaceutical companies and others. From partners it receives upfront payments, milestone fees according to development progress, and product sales and royalties after launch. It designs a revenue model for each pipeline candidate and aims to grow while balancing risk and return.
Summarized from the annual securities report (fiscal year ended December 2025) filed on EDINET.
Position within Pharmaceuticals (79 companies)
| PBR | 4.23x | Above the sector median of 1.86x (No. 64 from the lowest) |
|---|---|---|
| ROE | -67.83% | No. 48 in the sector (highest first); median 4.17% |
| Market cap | ¥7.5 bn | No. 51 in the sector (largest first) |
Ranks among stocks in the same Tokyo Stock Exchange sector (33 sectors). PER and PBR of zero or below (losses, negative equity) are excluded and ranked from the lowest.
Price milestones
| 52-week high | ¥129 | 2025/12/1 |
|---|---|---|
| 52-week low | ¥38 | 11/13 |
| Current position | 75.8% | Where the low is 0% and the high is 100% (close on 11/20: ¥107) |
| Year to date | -0.9% | No. 18 of 77 in the sector (best first) |
| 1 year | -12.3% |
Based on closing prices (adjusted for stock splits, excluding dividends).
Kabutaro's ranking history
| Top 50 gainers | 3 times | Latest: 11/20 (No. 1) |
|---|---|---|
| Top 50 losers | 5 times | Latest: 11/18 (No. 47) |
Gainers and losers have been recorded since 9/2026.
Calculated as of 2026/11/20 17:30 JST. Updated every business day in the evening.
Recent disclosures (TDnet, in Japanese)
- 11/17 17:30第三者割当により発行された第35回新株予約権(行使価額修正条項付)の行使完了及び月間行使状況に関するお知らせ
- 11/13 15:30営業外収益及び営業外費用の計上に関するお知らせ
- 11/13 15:302026年12月期 第3四半期決算短信〔日本基準〕(連結)
- 11/12 17:10第三者割当により発行された第35回新株予約権(行使価額修正条項付)の大量行使に関するお知らせ
- 11/02 08:50第三者割当により発行された第35回新株予約権(行使価額修正条項付)の月間行使状況に関するお知らせ
- 10/30 15:30Terrainとの米国における“Bondlido”販売提携と上市時期について
- 10/07 08:50東京証券取引所「スタンダード市場」への市場区分変更に関するお知らせ
- 10/01 08:50第三者割当により発行された第35回新株予約権(行使価額修正条項付)の月間行使状況に関するお知らせ
- 09/30 17:00東京証券取引所「スタンダード市場」への市場区分変更承認に関するお知らせ
- 09/30 15:30Terrainとの米国における“Bondlido”販売提携と上市時期について
Filings from the past 12 months (10).
Posts
This board is shared with the Japanese and Chinese versions. Feel free to write in English, Chinese or Japanese.
Write on the Medrx Co.,Ltd. board
More Japanese stocks in English
- PeptiDream Inc.4587
- Oncolys BioPharma Inc.4588
- PLAN DO Co.,Ltd.458A
- RIBOMIC Inc.4591
- SanBio Company Limited4592
- HEALIOS K.K.4593
- BrightPath Biotherapeutics Co.,Ltd.4594
- MIZUHO MEDY CO.,LTD.4595
- Kubota Pharmaceutical Holdings Co.,Ltd.4596
- Solasia Pharma K.K.4597
- Delta-Fly Pharma,Inc.4598
- StemRIM Inc.4599